LabCompass

Khalid A. Alamer

Medicine · Purdue University West Lafayette

OpenAlex ORCID
Early career · publishing since 2020Rising activity
Pharmaceutical Practices and Patient OutcomesMedication Adherence and ComplianceDiabetes Treatment and ManagementIntensive Care Unit Cognitive DisordersAntibiotic Use and Resistance

Publications

28

Citations

59

Est. group size

~2

Recurring co-author estimate

Active years

7

Publishing since 2020

Research summary
AI-generated

Khalid A. Alamer's research focuses on medication safety and appropriate use, especially in older adults with chronic conditions like diabetes and hypertension. His work includes studies on polypharmacy, deprescribing (the process of reducing or stopping unnecessary medications), drug monitoring, medication adherence, and real-world outcomes of drugs used for diabetes, kidney disease, and infections, often using large pharmacovigilance databases and surveys conducted in Saudi Arabia.

Medication safety and deprescribingPolypharmacy in older adultsDiabetes and chronic disease drug therapyPharmacoepidemiology and adverse event reportingMedication adherence and public health surveys

Publication output was minimal or absent before 2022 but has grown sharply since 2024, indicating a recent and rapidly increasing pace of research activity.

Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026

Publication cadence
Publications per year over the last 10 years — averaging 5.2/year recently
1718192020: 1 publication20212022: 2 publications22232024: 7 publications242025: 12 publications12252026: 5 publications26
Recent publications
Publishes in
  • Patient Preference and Adherence×3
  • Pharmaceuticals×3
  • Research in Social and Administrative Pharmacy×2
  • Medicine×1
  • Frontiers in Public Health×1
Similar researchers
By research-topic overlap

This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.

Last updated Jul 20, 2026.

Claim or correct this profile